O&G · Reproductive endocrinology & infertility
Hyperprolactinaemia: prolactinoma diagnosis (macroprolactin, MRI pituitary), cabergoline management, pregnancy considerations
Also known as Hyperprolactinemia · Elevated prolactin · Prolactinoma · Pituitary adenoma prolactin-secreting · Macroprolactinaemia · Cabergoline · Dopamine agonist · Galactorrhoea workup
Exam-exhaustive FRANZCOG fellowship topic on hyperprolactinaemia. Walks the clinical presentation (oligomenorrhoea, galactorrhoea, hypogonadism, visual symptoms with macroprolactinoma), the investigation ladder (pregnancy exclusion, prolactin with macroprolactin interference, TFT, MRI pituitary with gadolinium), the classification (micro- vs macro-adenoma 10 mm threshold, stalk effect versus true secretion), the management (cabergoline preferred over bromocriptine, dose titration, dopamine agonist withdrawal criteria), and pregnancy considerations (visual field monitoring, dopamine agonist safety, breastfeeding). Hyperprolactinaemia is a common cause of secondary amenorrhoea and sits in the Pituitary arm of the FIGO HyPO-P (hypothalamic, pituitary, ovarian, PCOS) classification; this topic covers the workup and management end to end.
Checked against its sources on 12 Sept 2026
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Acute severe headache with visual loss, ophthalmoplegia, and altered consciousness in a known or new pituitary adenoma — pituitary apoplexy; urgent MRI, hydrocortisone 100 to 200 mg IV bolus before imaging, neurosurgical decompression if vision or neurology deteriorates
- Bitemporal hemianopia on confrontation with secondary amenorrhoea and a prolactin over 250 micrograms per litre — macroprolactinoma with chiasmal compression; start cabergoline urgently, arrange pituitary surgery input, urgent MRI with gadolinium
- Pregnant woman with a known macroprolactinoma — monthly clinical review with visual field evaluation every 3 months; MRI pituitary without gadolinium if growth suspected; maintenance dopamine agonist therapy is an option for large macroprolactinomas; do not stop dopamine agonist without review
- Pituitary mass with a disproportionately low prolactin for its size (under the 200 ng/mL prolactinoma threshold) — likely stalk effect from a non-functioning adenoma, NOT a true prolactinoma; treatment is surgery, NOT escalating dopamine agonist (which would mask tumour growth)
- Patient on an antipsychotic (risperidone, amisulpride, haloperidol) with new amenorrhoea and galactorrhoea — drug-induced hyperprolactinaemia; review with psychiatry before imaging; consider switching to a prolactin-sparing agent (aripiprazole is the consensus-named choice)
- Hyperprolactinaemia in pregnancy with new visual symptoms — do NOT assume physiological; MRI without gadolinium; consider delivery if vision threatened
A 28-year-old teacher presents with three months of secondary amenorrhoea, intermittent galactorrhoea she had not mentioned until asked, and decreased libido. Her medication list includes risperidone for bipolar disorder. A 42-year-old man presents with headaches, bitemporal hemianopia, erectile dysfunction, and a prolactin of 4,200 micrograms per litre. A 36-year-old woman with a known microprolactinoma on cabergoline 0.5 mg twice weekly is now 8 weeks pregnant and asks whether to stop the medication. None of these is the same problem, but each test of management is the same principle — confirm the prolactin is real, identify the mechanism, choose cabergoline first-line, and tailor the dose to the patient.[1][3]
References11ShowHide
- [1]Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2011.PMID 21296991
- [2]Oğuz O, Palaoğlu KE, Incir S. Prevalence and re-evaluation of macroprolactinemia in hyperprolactinemic patients: a retrospective study in the Turkish population. Clin Chem Lab Med, 2025.PMID 40183492
- [3]Puzio A, Hylinska M, Kapała O, et al. Beyond normalization: rethinking optimal prolactin levels in prolactinoma management. Expert Rev Endocrinol Metab, 2026.PMID 42191233
- [4]Cai X, Zhu J, Yang J, et al. Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis. Chin Neurosurg J, 2022.PMID 35395837
- [6]Otis AS, Brochet MS, Tremblay Z, et al. Cabergoline Use and Pregnancy Outcomes: A Systematic Review. Birth Defects Res, 2025.PMID 40116053
- [7]Giri S, Suryadevara V, Ramesh AS, et al. The Spectrum of Serum Prolactin Levels in Patients with Non-Functioning Sellar Masses: A Retrospective Analysis. Neurol India, 2026.PMID 41817061
- [8]Sakata K, Hashimoto A, Takeshige N, et al. Clinical and radiographic characteristics of patients with non-functioning pituitary adenomas categorized according to their serum prolactin levels. Endocrine, 2024.PMID 38664336
- [9]Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol, 2023.PMID 37670148
- [12]Balen AH, Tamblyn J, Skorupskaite K, Munro MG A comprehensive review of the new FIGO classification of ovulatory disorders. Hum Reprod Update, 2024.PMID 38412452
- [16]Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf), 2006.PMID 16886971
- [15]Rajasekaran S, Vanderpump M, Baldeweg S, et al. UK guidelines for the management of pituitary apoplexy. Clin Endocrinol (Oxf), 2011.PMID 21044119